Drimva

Novartis

Principal Scientist I or II, PK Sciences Therapeutic Areas (Multiple Listings)

$108K–$222K

Cambridge (USA) · Principal · Full-time · Posted Jun 11, 2026

Experience
Minimum of 0–2 years in drug discovery and/or development in a relevant environment; 2+ years in a lead ADME/DMPK project strategy role preferred for Principal Scientist II.
Education
Ph.D. / Pharm.D.

About the job

Develops and implements pharmacokinetic and clinical pharmacology strategies for drug candidates, supporting project teams from discovery through late clinical development.

What you'll do

  • Represent PK Sciences in project teams and provide pharmacokinetic, drug metabolism, and clinical pharmacology expertise.
  • Develop dosing strategies and clinical pharmacology plans; contribute to study design and analyze PK and PK/PD data.
  • Prepare pharmacokinetic and clinical pharmacology documentation for regulatory submissions and use AI/ML approaches for modeling, automation, and predictive work.

What they ask for

  • Ph.D. / Pharm.D. with relevant experience in clinical pharmacology, drug metabolism and pharmacokinetics, or a related background.
  • Extensive knowledge of pharmacokinetics, drug metabolism, and PK/PD evaluation.
  • Experience working in project teams and cross-functional, matrixed environments; strong oral and written communication skills.

Nice to have

  • 2+ years in a lead role overseeing ADME/DMPK project strategy for consideration at Principal Scientist II.
  • Hands-on project experience with Artificial intelligence (AI) / Machine Learning (ML) approaches.

Pay

USD $108,500 and $201,500 per year (base salary); USD $119,700 and $222,300 per year (base salary)

Tools

Artificial intelligence (AI), Machine Learning (ML), ADME, DMPK, Modeling & Simulation (M&S), PK/PD, IND/IMPDs, NDA/BLAs

AI focus

Use AI/ML for model-guided molecular design, preclinical and clinical data automation, regulatory document authoring, predictive models, and improved insight generation and productivity.

Model-written summary · the original posting is authoritative

First seen Oct 28, 2026 · Last verified Nov 6, 2026 (UTC)